FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1995533274> ?p ?o ?g. }

• W1995533274 endingPage "950" @default.
• W1995533274 startingPage "946" @default.
• W1995533274 abstract "Objective To examine the ability of surgery as initial management in avoiding androgen deprivation therapy (ADT) in patients with high-risk localized prostate cancer. Materials and Methods A total of 267 men were identified from a cohort of patients treated by radical prostatectomy (RP) between January 1998 and June 2004. Patients were included if they presented with clinical stage ≥T2b and/or prostate-specific antigen (PSA) ≥15 ng/mL, and/or Gleason score ≥8. Information on biochemical recurrence, distant metastasis, cancer-specific survival, and use of ADT was obtained from a prospectively maintained database. Results The median follow-up was 6.7 years (range, 1-146 months). Biochemical recurrence (BCR), distant metastasis (DM), and prostate cancer–specific mortality (PCSM) were observed in 112 (42%), 28 (10%), and 15 (6%) patients, respectively. Salvage treatment was performed in 95 (85%) of 112 patients with BCR. Only 71 (27%) of 267 men were subjected to ADT. Overall, 8-year probabilities of freedom from BCR, DM, PCSM, and ADT were 46% (95% CI, 38-54), 87% (95% CI, 84-90), 93% (95% CI, 91-95), and 71% (95% CI, 65-77), respectively. Conclusions RP provides excellent long-term clinical outcomes for patients with high-risk localized prostate cancer and avoids the use of ADT in approximately 70% of these patients. To examine the ability of surgery as initial management in avoiding androgen deprivation therapy (ADT) in patients with high-risk localized prostate cancer. A total of 267 men were identified from a cohort of patients treated by radical prostatectomy (RP) between January 1998 and June 2004. Patients were included if they presented with clinical stage ≥T2b and/or prostate-specific antigen (PSA) ≥15 ng/mL, and/or Gleason score ≥8. Information on biochemical recurrence, distant metastasis, cancer-specific survival, and use of ADT was obtained from a prospectively maintained database. The median follow-up was 6.7 years (range, 1-146 months). Biochemical recurrence (BCR), distant metastasis (DM), and prostate cancer–specific mortality (PCSM) were observed in 112 (42%), 28 (10%), and 15 (6%) patients, respectively. Salvage treatment was performed in 95 (85%) of 112 patients with BCR. Only 71 (27%) of 267 men were subjected to ADT. Overall, 8-year probabilities of freedom from BCR, DM, PCSM, and ADT were 46% (95% CI, 38-54), 87% (95% CI, 84-90), 93% (95% CI, 91-95), and 71% (95% CI, 65-77), respectively. RP provides excellent long-term clinical outcomes for patients with high-risk localized prostate cancer and avoids the use of ADT in approximately 70% of these patients." @default.
• W1995533274 created "2016-06-24" @default.
• W1995533274 creator A5001069772 @default.
• W1995533274 creator A5013908031 @default.
• W1995533274 creator A5017841270 @default.
• W1995533274 creator A5033827148 @default.
• W1995533274 creator A5068011236 @default.
• W1995533274 creator A5068766594 @default.
• W1995533274 creator A5077333954 @default.
• W1995533274 date "2011-04-01" @default.
• W1995533274 modified "2023-09-25" @default.
• W1995533274 title "Avoiding Androgen Deprivation Therapy in Men With High-risk Prostate Cancer: The Role of Radical Prostatectomy as Initial Treatment" @default.
• W1995533274 cites W1980434476 @default.
• W1995533274 cites W1985587689 @default.
• W1995533274 cites W1986345593 @default.
• W1995533274 cites W1987109043 @default.
• W1995533274 cites W1998046820 @default.
• W1995533274 cites W2000385281 @default.
• W1995533274 cites W2007851922 @default.
• W1995533274 cites W2011005649 @default.
• W1995533274 cites W2029963458 @default.
• W1995533274 cites W2053696391 @default.
• W1995533274 cites W2069954157 @default.
• W1995533274 cites W2074621482 @default.
• W1995533274 cites W2075007329 @default.
• W1995533274 cites W2082569997 @default.
• W1995533274 cites W2092566016 @default.
• W1995533274 cites W2094616039 @default.
• W1995533274 cites W2098998490 @default.
• W1995533274 cites W2101889062 @default.
• W1995533274 cites W2105310697 @default.
• W1995533274 cites W2108941029 @default.
• W1995533274 cites W2135312889 @default.
• W1995533274 cites W2137491531 @default.
• W1995533274 cites W2137571400 @default.
• W1995533274 cites W2142547901 @default.
• W1995533274 cites W2145274312 @default.
• W1995533274 cites W2148539277 @default.
• W1995533274 cites W2156306108 @default.
• W1995533274 cites W2156357292 @default.
• W1995533274 cites W2163144362 @default.
• W1995533274 cites W2316095838 @default.
• W1995533274 doi "https://doi.org/10.1016/j.urology.2010.11.057" @default.
• W1995533274 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21477723" @default.
• W1995533274 hasPublicationYear "2011" @default.
• W1995533274 type Work @default.
• W1995533274 sameAs 1995533274 @default.
• W1995533274 citedByCount "19" @default.
• W1995533274 countsByYear W19955332742012 @default.
• W1995533274 countsByYear W19955332742013 @default.
• W1995533274 countsByYear W19955332742014 @default.
• W1995533274 countsByYear W19955332742015 @default.
• W1995533274 countsByYear W19955332742016 @default.
• W1995533274 countsByYear W19955332742018 @default.
• W1995533274 countsByYear W19955332742020 @default.
• W1995533274 countsByYear W19955332742021 @default.
• W1995533274 countsByYear W19955332742022 @default.
• W1995533274 crossrefType "journal-article" @default.
• W1995533274 hasAuthorship W1995533274A5001069772 @default.
• W1995533274 hasAuthorship W1995533274A5013908031 @default.
• W1995533274 hasAuthorship W1995533274A5017841270 @default.
• W1995533274 hasAuthorship W1995533274A5033827148 @default.
• W1995533274 hasAuthorship W1995533274A5068011236 @default.
• W1995533274 hasAuthorship W1995533274A5068766594 @default.
• W1995533274 hasAuthorship W1995533274A5077333954 @default.
• W1995533274 hasConcept C121608353 @default.
• W1995533274 hasConcept C126322002 @default.
• W1995533274 hasConcept C126894567 @default.
• W1995533274 hasConcept C141071460 @default.
• W1995533274 hasConcept C143998085 @default.
• W1995533274 hasConcept C2776235491 @default.
• W1995533274 hasConcept C2777008409 @default.
• W1995533274 hasConcept C2777899217 @default.
• W1995533274 hasConcept C2779013556 @default.
• W1995533274 hasConcept C2779466945 @default.
• W1995533274 hasConcept C2780192828 @default.
• W1995533274 hasConcept C2781406297 @default.
• W1995533274 hasConcept C71924100 @default.
• W1995533274 hasConcept C72563966 @default.
• W1995533274 hasConceptScore W1995533274C121608353 @default.
• W1995533274 hasConceptScore W1995533274C126322002 @default.
• W1995533274 hasConceptScore W1995533274C126894567 @default.
• W1995533274 hasConceptScore W1995533274C141071460 @default.
• W1995533274 hasConceptScore W1995533274C143998085 @default.
• W1995533274 hasConceptScore W1995533274C2776235491 @default.
• W1995533274 hasConceptScore W1995533274C2777008409 @default.
• W1995533274 hasConceptScore W1995533274C2777899217 @default.
• W1995533274 hasConceptScore W1995533274C2779013556 @default.
• W1995533274 hasConceptScore W1995533274C2779466945 @default.
• W1995533274 hasConceptScore W1995533274C2780192828 @default.
• W1995533274 hasConceptScore W1995533274C2781406297 @default.
• W1995533274 hasConceptScore W1995533274C71924100 @default.
• W1995533274 hasConceptScore W1995533274C72563966 @default.
• W1995533274 hasIssue "4" @default.
• W1995533274 hasLocation W19955332741 @default.
• W1995533274 hasLocation W19955332742 @default.
• W1995533274 hasOpenAccess W1995533274 @default.
• W1995533274 hasPrimaryLocation W19955332741 @default.

• next